Marie Bosslett, Assistant Editor

Symptoms of rosacea and dependence on oral medication were reduced in all 5 case studies.

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Positive results in melanin, erythema, wrinkles, texture, and periorbital dermal thickness were observed during the 8-week study.

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.

In case you missed it, this week we had news about rezpegaldesleukin’s fast track designation for AD, bimekizumab’s long-term efficacy for HS, conference recaps of SBS and MOPD, and more.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.

Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.

Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.

Botox Cosmetic has evolved from its accidental discovery to a leading treatment in dermatology, balancing medical innovation with ethical considerations.

The top videos under the hashtag, #spironolactone” had low scores on the mDISCERN and GQS scales, according to Adam Friedman, MD, FAAD, senior author of the study.

Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.

Mona Shahriari, MD, FAAD advocates for improving diversity in clinical imagery and trials to enhance trust in patients with skin of color.

The initiative, created by Quoin, promotes educational resources and study updates about the rare disease.

New data reveals an unmet need in the management of moderate to severe psoriasis in Greek patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

High concentrations of particulate matter can potentially lessen the exposure to UV radiation.

Patients saw improvement in hydration, sebum, erythema, and scarring after just 3 treatment sessions.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

Answer today’s poll and read more about the validity of dermatological content being shared on TikTok.

In case you missed it, this week we had news about awareness resources from the Skin Cancer Foundation, burn care disparities in skin of color, aesthetic insights for patients on medication-driven weight loss journeys, and more.

As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.

Learn more about the in-depth topics covered in the January 2025 print issue of Dermatology Times.

There are numerous ways for dermatologists to get involved in initiatives from the Skin Cancer Foundation, according to Becky Kamowitz.